Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

Posted On: 2019-12-12 22:30:43

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company and Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

Equillium had originally secured exclusive rights to develop and commercialize Biocon's novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017.

"Biocon is pleased with the development progress of itolizumab achieved by Equillium so far and has agreed to include Australia and New Zealand within the scope of the licensing agreement. As an innovation-led organization we are committed to bring novel therapeutics to the market to address unmet patient needs across the world. We look forward to our continued partnership with Equillium as they develop this molecule further for the treatment of severe autoimmune and inflammatory disorders," said Siddharth Mittal, CEO and Joint Managing Director, Biocon.

"We are pleased to deepen our relationship with Biocon by expanding our licensing agreement for itolizumab. Securing these rights helps strengthen and build upon our existing presence in Australia and New Zealand where we are collaborating with distinguished asthma centers and specialists to conduct the EQUIP clinical trial in uncontrolled asthma patients," said Bruce Steel, President and Chief Business Officer of Equillium.

Itolizumab is a novel first-in-class humanized anti-CD6 monoclonal antibody, which Biocon developed and launched in India under the brand name ALZUMAb™ to treat moderate to severe plaque psoriasis in 2013. In 2017, Biocon partnered with Equillium for this promising asset to develop it for a wide range of autoimmune disorders.

In addition to the EQUIP trial in uncontrolled asthma, Equillium is conducting Phase 1b proof-of-concept clinical trials of itolizumab for the treatment of acute graft-versus-host disease (aGVHD) and lupus nephritis. The U.S. Food and Drug Administration (FDA) granted itolizumab Fast Track designation for the treatment of aGVHD and lupus nephritis, as well as Orphan Drug designations for both the prevention and treatment of aGVHD.

Shares of BIOCON LTD. was last trading in BSE at Rs.293 as compared to the previous close of Rs. 290.4. The total number of shares traded during the day was 330364 in over 2829 trades.

The stock hit an intraday high of Rs. 294.2 and intraday low of 287.2. The net turnover during the day was Rs. 95834357.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Bisleri packs a punch: To give 200 tempos to distributors across the country in Phase 1

Syschem India Ltd reports loss in Q3 FY2020

HCL Technologies Launches a Dedicated Microsoft Business Unit

Jay Bharat Maruti Ltd Q3 consolidated net at Rs. 6.79 crore

Biocon Biologics India Ltd allots 50,25,463 shares to Activ Pine LLP

Bharti Airtel receives approval from DoT for enhancement of foreign investment in the company

Piramal Enterprises Limited's rights issue oversubscribed

Zee Entertainment Enterprises Ltd consolidated Q3 PAT drops to Rs. 349.43 crore

HDFC AMC Q3 PAT drops QoQ to Rs. 352.55 crore

Snowman Logistics announces Q3 2019-2020 results

Havells India Ltd Q3 consolidated PAT increases to Rs. 201.22 crore

Fire accident at Indian Card Clothing Company Ltd's Pimpri Plant

Hatsun Agro Product Ltd posts net profit of Rs. 27.88 crores in Q3 FY20

Olive by Embassy builds a next generation living community in India

Meera Industries Ltd revises record date to Feb 8, 2020

Mayur Uniquoters Ltd commissions new PU plant at Sitapur

IndiaMART InterMESH Ltd reports consolidated PAT of Rs. 62 crore in Q3

ZF Steering Gear India Ltd commences commercial production at Pithampur plant

Polycab India Ltd Q3 consolidated PAT up at Rs. 218.78 crore

Atishay Ltd posts Rs. 0.34 crore profit in Q3

Sasken Technologies Ltd Q3 consolidated net profit higher at Rs. 23.45 crore

HCL to Explore Technology-Powered Future of Digital Enterprises at the World Economic Forum 2020

Canara Bank appoints Shri Lingam Venkata Prabhakar as MD & CEO

Rajratan Global Wire Ltd reports consolidated PAT of Rs. 7.44 crore in Q3

Mahindra EPC Irrigation Ltd Q3 PAT surges to Rs. 7.77 crore

Manaksia Aluminium Company Ltd Q3 net profit at Rs. 1.42 crore

Sukhjit Starch & Chemicals Ltd posts consolidated net profit of Rs. 6.09 crore in Q3

Kamat Hotels India Ltd Q3 consolidated PAT jumps to Rs. 7.20 crore

Newgen Software Technologies Ltd consolidated Q3 PAT rises to Rs. 23.96 crores

ICRA A1+ rating of Dwarikesh Sugar Industries Ltd reaffirmed

ICICI Prudential Life Insurance Company Ltd consolidated Q3 net profit at Rs. 301.77 crores

Granules India Ltd board declares 3rd interim dividend of Rs. 0.25

Rane Madras Ltd posts consolidated loss of Rs. 7.17 crore in Q3 FY20

Granules India Ltd Q3 PAT up YoY, down QoQ

Granules India Ltd board approves buy back at Rs. 200 through tender offer route

Mindteck Recognized for Job Creation and Gender Parity in Kolkata's IT Sector

TCS a Leader in Life Sciences Data and Analytics Services for Sales and Marketing: Everest Group

Lupin Foundation Wins IDMA Corporate Citizen Award 2019

USFDA inspection at Alembic Pharmaceuticals Ltd's API facility at Karkhadi

Cosmo Films rewards its outstanding achievers through Chairman's Award

Federal Bank Profit surges 32% to Rs. 441 Crore backed by strong growth in Retail Franchise

ACE celebrates 25 years of Lifting India's Growth

JUST Dial Ltd Q3 consolidated PAT at Rs. 62.03 crore

Just Dial Ltd to acquire MyJD Private Ltd

Prestige Estates arm invests in Lokhandwala DB Realty LLP

Monnet Ispat & Energy Ltd reports consolidated net loss of Rs. 140.44 crores in Q3

HFCL consolidated Q3 net profit slides to Rs. 46.08 crore

Gujarat Hotels Ltd reports Q3 FY20 net profit of Rs. 1.09 crore

CRISIL upgrades bank facilities ratings of Sharat Industries Limited

SREI Infrastructure Finance Ltd board to consider issue of securities during FY2020-21







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019